NVO - Oramed And Oral Insulin: Can This Small Company Really Do It? April, 14 2022 04:02 PM Novo Nordisk A/S Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. This is a $15bn market, and there is very little competition. For further details see: Oramed And Oral Insulin: Can This Small Company Really Do It?